Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
Open accessThe DOI matches its Crossref record; 74 of the 77 references it cites were found in a registry or an index; none of the 86 sources its claims cite is checked for support yet.
Abstract
At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One of the major contributing factors is poor medication adherence.
Overview
CoChat Summary
## TL;DR
This review argues that poor medication adherence in type 2 diabetes is common, often affecting at least half of patients, and is tied to worse glycemic control, higher costs, and higher mortality. It highlights two broad modifiable drivers: treatment burden and patients’ treatment-related beliefs.
## Key findings
- Reported poor medication adherence in T2D ranged from 38% to 93% across studies, largely because definitions and methods varied; using MPR ≥80%, adherence was 47.3% for dipeptidyl peptidase-4 inhibitors, 41.2% for sulfonylureas, and 36.7% for thiazolidinediones in a 238,000-patient MarketScan analysis.
- Poor adherence was associated with worse outcomes: among >11,000 veterans, MPR <80% was significantly associated with poor glycemic control (HbA1c >8%, P<0.001); in 1,198 survey respondents, each 1-point drop in self-reported adherence was linked to a 0.21% increase in HbA1c and increases of 4.6%, 20.4%, and 20.9% in physician, ER, and hospital visits.
- Mortality was higher with poor adherence: in 15,984 UK patients, poor adherence and missed visits were each associated with a 1.6-fold increase in all-cause mortality (P<0.001); another study reported an odds ratio of 1.8 (P<0.001).
- Economic impact was substantial: improved adherence was projected to reduce hospitalization/ER risk by 13%, worsening adherence to raise it by 15%, and one analysis estimated annual savings of $4.7 billion with improved adherence and $3.6 billion with reduced poor adherence.
## Methods
- Narrative review of the literature on medication adherence in T2D, focusing on the scope of the problem, consequences, key contributors, interventions, and future developments.
- The paper synthesizes findings from retrospective/observational claim-database studies, surveys, and meta-analyses; it cites examples including analyses of 238,000 MarketScan patients, >11,000 veterans, 1,198 survey respondents, and other large database studies.
- Main analysis is qualitative synthesis of reported adherence rates, outcomes, and modifiable contributors, with attention to common adherence metrics such as medication possession ratio (MPR) ≥80% and persistence definitions.
## Limitations
- The paper states that much of the evidence comes from retrospective or observational claim-database studies using widely varying definitions, making findings difficult to interpret.
- It states that intervention evidence is limited because adherence measures vary widely, hard outcomes are often lacking, interventions are not clearly explained, and follow-up is often inadequate.
- Evident from the text: this is a review, not a new primary study, so its conclusions depend on the quality and comparability of the cited literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 1 Not valid · 57 Not checked · 17 Own results and interpretations
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes.”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In one study that tracked new prescriptions written electronically over a 12-month period for >75,000 patients, 31.4% of new prescriptions for diabetes drugs were never filled.25”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Scope of the problem
What the sources say
- Not matchedcites [25]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainn = 75,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes.”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“perceived patient burden regarding obtaining and taking their medications (eg, treatment complexity, out-of-pocket costs, and hypoglycemia)”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
49 more claims
Create a free account to see all 75 claims and every source verdict.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple factors contribute to inconsistent medication use and treatment discontinuation among people with diabetes, including perceived lack of medication ef fi cacy, fear of hypoglycemia, lack of access to medication, and adverse effects of medication (63).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2DM who discontinue or do not properly adhere to their therapy, there is an increased risk of microvascular and macrovascular complications [7], which can in turn increase healthcare costs further [5, 6].”
From Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The data from this survey highlight patient perspectives on reasons for treatment discontinuation among people with T2DM in the USA and UK and provide focal points for communication for these individuals when they are initiating new therapies [5].”
From Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the NICE guidance (NG28) and gastrointestinal tolerability are likely important drivers, early GLP‐1RA discontinuation is plausibly multifactorial and may also reflect perceived treatment effectiveness, complex dosing schedules, injection‐related barriers, limited access to diabetes education, economic constraints, and medication shortages. 19 , 32 , 33 , 34”
From Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Up to 50% of people with T2DM discontinue treatment by 1 year [5].”
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Interventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945 · cited 2×
“65 A key element is the need for greater consistency when measuring medication adherence, which require better instruments and tools for assessment.”
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Kennedy, L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70021-0 · Cited by 1,195
Ho, P. M., Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner, J. F., & Magid, D. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1836 · Cited by 1,135
The Economic Costs of Type 2 Diabetes: A Global Systematic Review
Seuring, T., Archangelidi, O., & Suhrcke, M. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0268-9 · Cited by 837 · cited 1×
“Even worse, it has been well documented that this cost burden has been inexorably growing worldwide.(10) A key contributor to the remarkably high rates of morbidity and mortality is chronic poor metabolic control, especially poor glycemic control.”
Adherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726 · cited 1×
“41 In their comprehensive review of 76 studies, Claxton et al 42 found that the prescribed number of doses per day was inversely associated with medication adherence; indeed, the mean adherence across studies decreased progressively from 79% with a once-daily dose to 51% with a four times daily…”
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Self-citationPrimary Medication Non-Adherence: Analysis of 195,930 Electronic Prescriptions
Fischer, M. A., Stedman, M. R., Lii, J., Vogeli, C., Shrank, W. H., Brookhart, M. A., & Weissman, J. S. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1253-9 · Cited by 572 · cited 1×
“25 This problem, often referred to as primary nonadherence, may be particularly relevant among patients who are refusing to initiate insulin or other injectable hypoglycemic therapy, typically due to injection phobia, inconvenience, poor patient–physician communication, and/or negative patient…”
Cited by
Items 101–200 of 761
Steenkamp, D., Eby, E. L., Gulati, N., & Liao, B. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821997923 · Cited by 33
Yang, W., Dong, X., Li, Q., Cheng, Z., Yuan, G., Liu, M. R., Xiao, J., Gu, S., Niemoeller, E., Chen, L., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14722 · Cited by 36
Quek, A., Kassim, N. K., Lim, P. C., et al. (2021) · Pharmaceutical Biology · doi:10.1080/13880209.2021.1948065 · Cited by 32
“These side effects along with the high cost of clinical drugs have led to the diabetic patients’ poor adherence to hypoglycaemic drugs (Polonsky and Henry 2016).”
BackgroundHolistic psychosocial determinants of adherence to medication in people with type 2 diabetes
Reach, G., Pellan, M., Crine, A., Touboul, C., Ciocca, A., & Djoudi, Y. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.06.001 · Cited by 38
Bartlett, Y. K., Farmer, A. A., Rea, R. D., & French, D. (2019) · Journal of Medical Internet Research · doi:10.2196/15989 · Cited by 32
“However, adherence to and persistence with tablet medication is poor for at least half the population of people with type 2 diabetes prescribed these medications [2].”
BackgroundOwolabi, E. O., Goon, D. T., & Ajayi, A. I. (2020) · Medicine · doi:10.1097/md.0000000000018953 · Cited by 35
Majeed, A., Rehman, M., Hussain, I., Imran, I., Saleem, M. U., Saeed, H., Hashmi, F. K., Akbar, M., Abrar, M., Ramzan, B., et al. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s295012 · Cited by 48
Ata, F., Khan, A. A., Khamees, I., Iqbal, P., Yousaf, Z., Mohammed, B. Z. M., Aboshdid, R. K., Marzouk, S., Barjas, H., Khalid, M., et al. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2175031 · Cited by 35
Qin, L., Chen, S., Flood, E. M., Shaunik, A., Romero, B., de la Cruz, M., Alvarez, C., & Grandy, S. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0237-8 · Cited by 36
Schneider, E. L., Hearn, B. R., Pfaff, S. J., Reid, R. R., Parkes, D. G., Vrang, N., Ashley, G. W., & Santi, D. V. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00218 · Cited by 32
The impact of mobile applications on medication adherence: a systematic review
Ng, R., Carter, S. R., & El-Den, S. (2019) · Translational Behavioral Medicine · doi:10.1093/tbm/ibz125 · Cited by 31
Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes
Yoon, K., Kang, J., Kwon, S. C., TRAUTMANN, M. E., Hompesch, M., Stewart, J. A., & SORLI, C. H. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14032 · Cited by 32
“However, there exists an unmet need for a GLP-1RA with a longer duration of efficacy that could permit less frequent dosing (eg, >1 week) and help facilitate treatment adherence and subsequently improve glycaemic control.(8,11) Long-acting GLP-1RAs administered once weekly could also allow greater dosing flexibility a…”
BackgroundOduro, P. K., Fang, J., Niu, L., Li, Y., Li, L., Zhao, X., & Wang, Q. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104893 · Cited by 30
Rea, F., Ciardullo, S., Savaré, L., Perseghin, G., & Corrao, G. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109035 · Cited by 33
Ishii, H., Shin, H., Tosaki, T., Haga, T., Nakajima, Y., Shiraiwa, T., Watanabe, N., Koizumi, M., Nakajima, H., Okada, S., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0414-4 · Cited by 34
Al-Qerem, W. A., Jarab, A. S., Badinjki, M., Hyassat, D., & Qarqaz, R. (2021) · PLoS ONE · doi:10.1371/journal.pone.0256666 · Cited by 38
Impaired Awareness of Hypoglycaemia in Insulin-treated Type 2 Diabetes Mellitus
Alkhatatbeh, M. J., Abdalqader, N. A., & Alqudah, M. A. Y. (2018) · Current Diabetes Reviews · doi:10.2174/1573399814666180806144937 · Cited by 30
Abate, T. W. (2019) · BMC Research Notes · doi:10.1186/s13104-019-4205-4 · Cited by 33
Masaba, B. B., & Mmusi-Phetoe, R. (2021) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s270137 · Cited by 39
“Not surprisingly, treatment adherence becomes more challenging when the treatment itself is perceived as more difficult, onerous, or burdensome.(13) In Iran it was found that non-adherence among patients with T2DM was influenced by lack of a deep understanding of the medical knowledge on diabetes in many aspects, and…”
BackgroundResultInfluentialHealth care delivery model in India with relevance to diabetes care
Das, A. K., Saboo, B., Maheshwari, A., Nair, M., Banerjee, S., Jayakumar, C., Benny, P., V, Sunil Prasobh, P., Mohan, A. R., Potty, V. S., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e10904 · Cited by 34
Grunberger, G., Sze, D., Ermakova, A., Sieradzan, R., Oliveria, T., & Miller, E. M. (2020) · Clinical Diabetes · doi:10.2337/cd19-0008 · Cited by 28
“It is widely recognized that glycemic control is suboptimal in many patients with type 2 diabetes (1,2).”
BackgroundMatlock, K. A., Broadley, M. M., Hendrieckx, C., Clowes, M., Sutton, A., Heller, S. R., de Galan, B. E., Pouwer, F., & Speight, J. (2021) · Diabetic Medicine · doi:10.1111/dme.14706 · Cited by 31
McCrimmon, R. J., Sifri, S. A., Emral, R., Mohan, V., Sauque‐Reyna, L., Trescolí, C., Lalic, N. M., Alvarez, A., Demil, N., Coudert, M., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14354 · Cited by 31
Nakajima, H., Okada, S., Mohri, T., Kanda, E., Inaba, N., Hirasawa, Y., Seino, H., Kuroda, H., Hiyoshi, T., Niiya, T., et al. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0313-x · Cited by 33
“It has been reported that improved quality of life (QOL) results in improved adherence with medication [18] and poor adherence contributes to poor glycemic control [19].”
BackgroundMikhael, E. M., Hussain, S. A., Shawky, N., & Hassali, M. A. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000658 · Cited by 32
“InTRoduCTIon Diabetes mellitus (DM) is a chronic metabolic disorder that has shown a dramatically increased incidence in recent decades.1 DM can cause many acute and chronic complications that may be associated with significant morbidity and mortality.2 3 Glycemic control can effectively reduce diabetic complications…”
BackgroundInfluentialChan, J. C. N., Paldánius, P. M., Mathieu, C., Stümvoll, M., Matthews, D. R., & Prato, S. D. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14192 · Cited by 34
“The lack of long-term efficacy and safety data of pharmacological interventions may contribute towards the delayed treatment initiation and intensification in patients with YOD.(5) Apart from causing long-term complications, the burden of hyperglycaemia can accelerate beta-cell failure, leading to early treatment esca…”
BackgroundInfluentialManagement of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
Kane, M. P., Triplitt, C. L., & Solis‐Herrera, C. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa413 · Cited by 41
“However, some patients may prefer oral over injectable medications,(5,12) and lower treatment adherence has been reported when patients perceive a treatment as difficult or inconvenient.(12) Oral semaglutide, the first GLP-1RA developed for oral administration, was approved by the US Food and Drug Administration (FDA)…”
BackgroundCare-seeking and managing diabetes in rural Bangladesh: a mixed methods study
Jennings, H. M., Morrison, J., Akter, K., Haghparast‐Bidgoli, H., King, C., Ahmed, N., Kuddus, A., Shaha, S. K., Nahar, T., Azad, K., et al. (2021) · BMC Public Health · doi:10.1186/s12889-021-11395-3 · Cited by 34
“Poor medication adherence often indicates a lack of integrated and patient-centred care [30].”
BackgroundMody, R., Manjelievskaia, J., Marchlewicz, E. H., Malik, R. E., Zimmerman, N. M., Irwin, D. E., & Yu, M. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.01.017 · Cited by 22
Wilson-Anumudu, F. J., Quan, R., Castro, C. M., Cerrada, C. J., Juusola, J. L., Turken, M., & Jasik, C. B. (2021) · JMIR Diabetes · doi:10.2196/25295 · Cited by 30
Bonikowska, I., Szwamel, K., & Uchmanowicz, I. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18168658 · Cited by 37
“[38] found at least 45% of patients with T2DM did not achieve adequate glycemic control (HbA1c < 7%).”
BackgroundShahabi, N. A., Fakhri, Y., Aghamolaei, T., Hosseini, Z., & Homayuni, A. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.03.005 · Cited by 29
Tunsuchart, K., Lerttrakarnnon, P., Srithanaviboonchai, K., Likhitsathian, S., & Skulphan, S. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17155564 · Cited by 25
“For example, in this study data were not collected on the patients’ medication knowledge [36], education level, income, perceived treatment inefficacy, treatment complexity or on hypoglycemia [37].”
BackgroundGautier, J., Boîtard, C., Michiels, Y., Raymond, G., Vergez, G., & Guedon, G. (2021) · Patient Education and Counseling · doi:10.1016/j.pec.2021.02.022 · Cited by 30
Kalyani, R. R., Allende-Vigo, M. Z., Antinori-Lent, K. J., Close, K. L., Das, S. R., Deroze, P., Edelman, S. V., El Sayed, N. A., Kerr, D., Neumiller, J. J., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad745 · Cited by 25
Shuey, M. M., Lee, K. M., Keaton, J. M., Khankari, N. K., Breeyear, J. H., Walker, V. M., Miller, D. R., Heberer, K. R., Reaven, P. D., Clarke, S. L., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104674 · Cited by 29
Janssen, E. M., Longo, D. R., Bardsley, J. K., & Bridges, J. F. P. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s139471 · Cited by 27
“This priority could indicate that people with lower levels of education are more bothered by treatment burden which could decrease adherence if treatment burden is not considered in clinical care.(44) People with some college or less education were willing to allocate more of their budget to 4 days of stable blood glu…”
Alexopoulos, A.-S., & Buse, J. B. (2019) · Metabolism · doi:10.1016/j.metabol.2019.06.012 · Cited by 24
“[37] Likewise, adherence is better for insulin pens than insulin administered by vial and syringe.[36, 38] Hence, when comparing ease of use between medication classes, differences will be wider between GLP-1 RAs and insulin administered by vial and syringe, versus GLP-1 RAs and insulin delivered via pen; the latter c…”
BackgroundYazew, K. G., Walle, T. A., & Azagew, A. W. (2019) · International Journal of Africa Nursing Sciences · doi:10.1016/j.ijans.2019.100167 · Cited by 33
Kruger, D. F., & Anderson, J. E. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0193 · Cited by 30
“117 Clinicians are challenged to intensify therapy by different barriers, including restrictions on time and resources, 118,119 inaccurate or incomplete glucose data, 120–122 lack of decision support tools, 123 and concerns about hypoglycemia.”
Han, Y., Spicer, J. A., Huang, Y., Bunt, C. R., Liu, M., & Wen, J. (2024) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.202300271 · Cited by 31
Beernink, J. M., Oosterwijk, M. M., Khunti, K., Gupta, P., Patel, P., van Boven, J. F. M., Heerspink, H. J. L., Bakker, S. J. L., Navis, G. J., Nijboer, R. M., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2533 · Cited by 29
Lane, D., Patel, P., Khunti, K., & Gupta, P. (2019) · Patient Preference and Adherence · doi:10.2147/ppa.s162215 · Cited by 29
“Research broadly agrees that non-adherence is common in people with DM; however, studies presenting non-adherence prevalence generally have inconsistent findings (38%–93% poor adherence).(34) This inconsistency is also found when considering medication persistence (adherence over time), with a systematic review presen…”
BackgroundAldemir, İ. D., Doğulu, C., & Bozo, Ö. (2019) · Current Psychology · doi:10.1007/s12144-019-00309-7 · Cited by 29
Rani, M. A., & Shriraam, V. (2019) · Journal of Primary Care & Community Health · doi:10.1177/2150132719865820 · Cited by 36
“Compliance to treatment guidelines helps the patient achieve target glucose level and reduces risk of diabetic complications and mortality.(7,8) However, diabetes self-care measures demand a high level of motivation and consistent efforts from the patients Previous research works have reported poor compliance to self-…”
BackgroundLong-term metformin adherence in the Diabetes Prevention Program Outcomes Study
Walker, E. A., Gonzalez, J. S., Tripputi, M., Dagogo-Jack, S. E., Matulik, M. J., Montez, M. G., Tadros, S. S., & Edelstein, S. L. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001537 · Cited by 25
Oliveira, H. C., Neto, D. H., Carvalho, S. D. L., de Barros, R. D. C. L., Neves, M. L. D. S., Andrechuk, C. R. S., Alexandre, N. M. C., Ribeiro, P. A. B., & Rodrigues, R. C. M. (2023) · Systematic Reviews · doi:10.1186/s13643-023-02340-z · Cited by 28
“Medication adherence has a major impact on reducing mortality and healthcare costs related to the treatment of noncommunicable diseases (NCDs), especially cardio-vascular diseases (CVDs) and diabetes mellitus [1–3].”
BackgroundHorii, T., Masudo, C., Takayanagi, Y., Oikawa, Y., Shimada, A., & Mihara, K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14265 · Cited by 27
“One factor hindering the proactive use of traditional GLP-1RAs is the need for subcutaneous administration, given that some patients prefer oral medications to injectables 5,6 , and a reported decline in treatment adherence with injections 6,7 .”
BackgroundOptimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach
Isaacs, D. M., Kruger, D. F., & Spollett, G. R. (2020) · Diabetes Spectrum · doi:10.2337/ds20-0016 · Cited by 26
Stecher, C. D., Mukasa, B., & Linnemayr, S. (2020) · Journal of Health Economics · doi:10.1016/j.jhealeco.2021.102443 · Cited by 25
Boye, K. S., Mody, R., Lage, M. J., Douglas, S. D., & Patel, H. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00838-6 · Cited by 30
Fan, Q., Ong, A. S. E., Koh, M. S., et al. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106673 · Cited by 21
Contreras‐Vergara, A. L., Sifuentes-Franco, S., Haack, S. L., Graciano‐Machuca, O., Rodríguez-Carrizález, A. D., López-Contreras, A. K., Reyes‐Pérez, I. V., & Huerta-Olvera, S. G. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s370323 · Cited by 31
“7%).(27) The probability that patients adhere to their treatment is 1.”
BackgroundSmith, K., Davies, K. A. B., Stevenson, E., & West, D. J. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.587843 · Cited by 24
“Given the importance of weight management in the care and prevention of T2D (12), and where higher out-ofpocket costs are associated with poor adherence to anti-diabetic treatments (50), this needs careful consideration when designing long-term trials or assessing current evidence.”
BackgroundVanadium(IV)-diamine complex with hypoglycemic activity and a reduction in testicular atrophy
de Lima, L. M. A., Belian, M. F., Silva, W. E., Postal, K., Kostenkova, K., Crans, D. C., Rossiter, A. K. F. F., & da Silva, V. A. (2020) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2020.111312 · Cited by 21
Khunti, K., Gavin, J. R., Boulton, A. J. M., Blickstead, R., McGill, M. J., Ceriello, A., Raz, I., SADIKOT, S. M., Wood, D., Cos, X., et al. (2018) · Primary care diabetes · doi:10.1016/j.pcd.2018.04.003 · Cited by 25
Billings, L. K., Winne, L., Sharma, P., Valderas, E. G., Chivukula, K. K., & Kwan, A. Y. M. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03849 · Cited by 28
Unni, E., Gupta, S., & Sternbach, N. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.018 · Cited by 24
Ağralı, H., & Akyar, İ. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.12.010 · Cited by 30
Polonsky, W. H., Giorgino, F., Rosenstock, J., Whitmire, K., Lew, E., Coudert, M., Alvarez, A., Nicholls, C. J., & McCrimmon, R. J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14822 · Cited by 22
Self-citationBenrazavy, L., & Khalooei, A. (2019) · Shiraz E-Medical Journal · doi:10.5812/semj.84746 · Cited by 27
Electrical stimulation of renal nerves for modulating urine glucose excretion in rats
Jiman, A. A., Chhabra, K. H., Lewis, A. G., Cederna, P. S., Seeley, R. J., Low, M. J., & Bruns, T. M. (2018) · Bioelectronic Medicine · doi:10.1186/s42234-018-0008-5 · Cited by 18
“Stimulation of renal nerves may provide an alternative treatment approach for glycemic control that avoids patient compliance issues typically seen with medications (Polonsky and Henry 2016).”
BackgroundChittem, M., Sridharan, S. G., Pongener, M., Maya, S., & Epton, T. (2022) · Chronic Illness · doi:10.1177/17423953211032251 · Cited by 19
“However, medication-management differ in westernized and Asian countries.(3,20) In westernized countries, physicians addressed patients’ needs to reduce medication complexity,(21,22) and used shared decisionmaking, which improved the physicianpatient relationship.”
BackgroundA Qualitative Study on Medication Taking Behaviour Among People With Diabetes in Australia
Ahmad, A., Khan, M. U., & Aslani, P. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.693748 · Cited by 22
Lee, H. S., Park, J. C., Chung, I., Liu, J., Lee, S., & Han, K. (2022) · Diabetes Care · doi:10.2337/dc21-2305 · Cited by 19
Diabetes Mellitus—Digital Solutions to Improve Medication Adherence: Scoping Review
Georgieva, N., Tenev, V., Kamusheva, M., & Petrova, G. I. (2023) · Diabetology · doi:10.3390/diabetology4040040 · Cited by 27
Roshan-Nejad, M., Hosseini, M., Vasli, P., Nasiri, M., & Hejazi, S. S. (2025) · Scientific Reports · doi:10.1038/s41598-024-84399-9 · Cited by 27
Feldman, E. C. H., Durkin, L. K., & Greenley, R. N. (2021) · Journal of Pediatric Nursing · doi:10.1016/j.pedn.2021.01.026 · Cited by 19
Bartlett, Y. K., Farmer, A. A., Newhouse, N., Miles, L. M., Kenning, C., & French, D. (2021) · JMIR Formative Research · doi:10.2196/30058 · Cited by 18
“Poor adherence to oral treatments is common in people with type 2 diabetes [1,2].”
Ding, A., Dixon, S. W., Ferries, E. A., & Shrank, W. H. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.3.379 · Cited by 24
Smith, K., Taylor, G., Brunsgaard, L. H., Walker, M., Davies, K. A. B., Stevenson, E., & West, D. J. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-002820 · Cited by 26
Vallis, M., Jin, S., Klimek-Abercrombie, A. M., Bunko, A., KUKASWADIA, A. A., Neish, C. S., & Ivers, N. M. (2022) · Diabetic Medicine · doi:10.1111/dme.14941 · Cited by 21
“8%, 42 strategies), followed by Shaping knowledge (4) (17.”
BackgroundMethodInfluentialDesta, R., Blumrosen, C., Laferriere, H. E., Saluja, A., Bruce, M. A., Elasy, T. A., Griffith, D. M., Norris, K. C., Cavanaugh, K. L., & Umeukeje, E. M. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s371162 · Cited by 23
“Poor medication adherence has been directly linked to increased risk of stroke from hypertension,(17) increased morbidity and mortality from hypertension,(17) diabetes(18) and kidney disease,(19) and greater healthcare cost.(18) Black patients report lower rates of medication adherence than White patients,(20) and giv…”
BackgroundBennett, B. L., & Puhl, R. M. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110827 · Cited by 30
“Patients with T2D already face a series of barriers to engaging in health-promoting behaviors including complicated medication regimes [42], lack of social support [43], and monetary expenses [43].”
BackgroundJeyalakshmi, K., Rao, M., Shashidhara, Y. N., Thunga, G., Ravishankar, N., Sudhakar, C., & Devi, E. S. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s380784 · Cited by 29
“Medication non-adherence or suboptimal adherence to the medications is a well-known factor that contributes to the poor control of blood pressure and glycaemic level.(7,8)”
BackgroundEbid, A. I. M., Ehab, M., Ismail, A., Soror, S. H. A., & Mahmoud, M. A. (2019) · Journal of Drug Assessment · doi:10.1080/21556660.2019.1619571 · Cited by 21
Garry, E. M., Schneeweiß, S., Eapen, S., Petruski‐Ivleva, N., Cheever, E., Murk, W. K., Rajan, A., Rassen, J. A., Gambino, D., Jang, H. J., et al. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.12.1442 · Cited by 19
Diabetes Self-Care Activities: A Community-Based Survey in an Urban Slum in Hyderabad, India
Chandrika, K., Das, B. N., Syed, S., & Challa, S. (2020) · Indian Journal of Community Medicine · doi:10.4103/ijcm.ijcm_236_19 · Cited by 13
Soudry-Kochavi, L., Naraykin, N., Paola, R. D., Gugliandolo, E., Peritore, A. F., Cuzzocrea, S., Ziv, E., Nassar, T., & Benita, S. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.10.013 · Cited by 19
Moosa, A., Bezuidenhout, S., Meyer, J. C., & Godman, B. (2019) · Journal of Pharmaceutical Health Services Research · doi:10.1111/jphs.12283 · Cited by 21
“We are aware that there have been a number of publications looking at key issues surrounding managing patients with T2DM including their knowledge and adherence to medicines([26,32,33]); however, we believe it is still important to explore key aspects in South Africa.”
BackgroundBeliefs about medicines as mediators in medication adherence in type 2 diabetes
Pereira, M. G., Ferreira, G., Machado, J. C., & Pedras, S. (2019) · International Journal of Nursing Practice · doi:10.1111/ijn.12768 · Cited by 22
Asthma management in the digital age
Bocian, I. Y., Chin, A. R., Rodriguez, A., Collins, W. J., Sindher, S., & Chinthrajah, R. S. (2024) · Frontiers in Allergy · doi:10.3389/falgy.2024.1451768 · Cited by 21
Type 2 diabetes in children and adolescents: Challenges for treatment and potential solutions
Jia, I. L. J., Zampetti, S., Pozzilli, P., & Buzzetti, R. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111879 · Cited by 31
Nikoviotis, R., & Ringas, D. (2021) · Panhellenic Conference on Informatics · doi:10.1145/3503823.3503910 · Cited by 17
“[18],[19] Monitoring has expanded beyond self-monitoring of blood glu-”
BackgroundMcCrimmon, R. J., CHENG, A. Y. Y., Galstyan, G. R., Djaballah, K., Li, X., Coudert, M., & Frías, J. P. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14844 · Cited by 17
“Individualization of therapy also requires the health care professional to be cognizant of other factors, including comorbidities, hypoglycaemia risk, patient preference(2) and how treatment complexity may affect adherence and persistance.(13) In particular, increasing number of injections can be perceived as burdenso…”
BackgroundPiragine, E., Petri, D., Giometto, S., Martelli, A., Lucenteforte, E., & Calderone, V. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106519 · Cited by 19
Borges, R. D. S., Conegundes, A. F., de Paula, L. H., dos Santos, R. L. C., Alves, S. N., Machado, R. A., Viana, I. B., & Silva, A. C. S. E. (2024) · Pediatric Diabetes · doi:10.1155/2024/6295345 · Cited by 23
“Nevertheless, concerns over adherence to injectable medications persist in pediatric patients, emphasizing the persistent need for the development and approval of new oral drugs [19, 21].”
Westergaard, L., Alifrangis, L. H., Buckley, S. T., Coester, H. V., Klitgaard, T., Kristensen, N. R., Nishimura, E., Nørgreen, L., Rocha, T. M. P., Steensgaard, D. B., et al. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01405-8 · Cited by 20
“Therefore, it is likely that a once-weekly fixed-ratio combination of basal insulin and GLP-1 RA could help mitigate the inertia often associated with insulin initiation and relieve the treatment burden of daily injections [7–9].”
Validation of diabetes medication adherence scale in the Lebanese population
Mallah, Z. I., Hammoud, Y., Awada, S., Rachidi, S., Zein, S., Ballout, H. A., & Al‐Hajje, A. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107837 · Cited by 19
Cardel, M. I., Ross, K. M., Butryn, M. L., Donahoo, W. T., Eastman, A., Dillard, J. R., Grummon, A. H., Hopkins, P., Whigham, L. D., & Janicke, D. M. (2020) · Nutrition and Diabetes · doi:10.1038/s41387-020-0106-9 · Cited by 21
Physician-patient alignment in satisfaction with psoriatic arthritis treatment in Latin America
Soriano, E. R., Zazzetti, F., Pereira, I. A., et al. (2020) · Clinical Rheumatology · doi:10.1007/s10067-019-04870-1 · Cited by 17
Improving Adherence in Type 2 Diabetes
Swe, K., & Reddy, S. S. K. (2020) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2020.04.007 · Cited by 21
Pednekar, P. P., Heller, D. A., & Peterson, A. M. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.9.1099 · Cited by 28
“These findings are consistent with earlier literature indicating that medication nonadherence is associated with greater risk of hospitalization, greater health care utilization, and higher health care costs.6,26,27,29,30,54-60 Lau et al. (2004) and Ho et al. (2008) reported that the odds of being hospitalized were 2.…”
InfluentialHIGHTON, P. J., Funnell, M. P., Gupta, P., Zaccardi, F., Lim, L., Seidu, S., & Khunti, K. (2025) · Diabetologia · doi:10.1007/s00125-025-06617-x · Cited by 36
“System‑related factors Effective communication between healthcare providers and patients also influences adherence rates; communication barriers and lack of shared decision making negatively impact adherence [52, 60], and reduced trust in physicians may also reduce medication adherence [52, 54].”
CHENG, A. Y. Y., Bailey, T. S., Mauricio, D., & Roussel, R. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3329 · Cited by 17
“Given that the fear of hypoglycaemia represents a barrier to effective insulin titration and glycaemic control, the demonstration of a lower risk of hypoglycaemia, especially during the period of greatest dose increases, may help to improve confidence of both patients and physicians to properly titrate and adhere to a…”
BackgroundMohamad, M. R., Moussally, K., Lakis, C., El-Hajj, M., Bahous, S. A., Peruzzo, C., Reid, A. J. S., & Edwards, J. K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251316 · Cited by 19
The Genetics of Adverse Drug Outcomes in Type 2 Diabetes: A Systematic Review
Baye, A. M., Fanta, T. G., Siddiqui, M. K., & Dawed, A. Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.675053 · Cited by 20
Lewinski, A. A., Jazowski, S. A., Goldstein, K. M., Whitney, C. A., Bosworth, H. B., & Zullig, L. L. (2022) · Patient Education and Counseling · doi:10.1016/j.pec.2022.08.005 · Cited by 22
Factors Affecting Performance of Insulin Pen Injector Technology: A Narrative Review
Sparre, T., Hammershøy, L., Steensgaard, D. B., Sturis, J., Vikkelsøe, P., & Azzarello, A. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221145201 · Cited by 18
Long-Term Efficacy and Safety of Nutritional and Pharmacological Strategies for Obesity
Barrea, L., Boschetti, M., Gangitano, E., Guglielmi, V., Verde, L., & Muscogiuri, G. (2025) · Current Obesity Reports · doi:10.1007/s13679-024-00602-y · Cited by 21
Metadata
- Authors
- Polonsky, W., & Henry, R.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Polonsky, William
- Venue
- Patient Preference and Adherence
- Publisher
- Informa UK Limited
- Published
- 2016-07
- Volume
- Volume 10
- Pages
- 1299-1307
- ISSN
- 1177-889X (ISSN-L)
- PMC
- PMC4966497
- OpenAlex
- W2493860075
- Cited by
- 784
- References
- 77
- Citations by year
- 2026: 93 · 2025: 97 · 2024: 89 · 2023: 82 · 2022: 108 · 2021: 106 · 2020: 106 · 2019: 54 · 2018: 34 · 2017: 13 · 2016: 2
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Patient Preference and Adherence (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Intarcia Therapeutics
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- medication adherence, type 2 diabetes, glycemic control, barriers to adherence, medication beliefs, medication burden, out-of-pocket costs, hypoglycemia, treatment complexity, clinical inertia, socioeconomic factors, diabetes complications, drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.